• HOME
  •  > 
  • 臨床医学：一般
  •  > 
  • 雑誌
  •  >  最新医学別冊　新しい診断と治療のABC3/呼吸器3　サルコイドーシス　改訂第2版

最新医学別冊　新しい診断と治療のABC3/呼吸器3　サルコイドーシス　改訂第2版

出版社： 最新医学社
発行日： 2012-05-25
分野： 臨床医学：一般  >  雑誌
ISSN： 03708241
雑誌名：
特集： サルコイドーシス　改訂第2版
電子書籍版： 2012-05-25 （改訂第2版）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学別冊　新しい診断と治療のABC3/呼吸器3　サルコイドーシス　改訂第2版

    ―目次―

    特集　サルコイドーシス　改訂第2版

    第１章　サルコイドーシスの概念・定義
    　序 　
    　眼で見るサルコイドーシス

    第1章　病理・病態生理
    　概念・定義・疫学 　
    　厚生労働省ガイドラインをめぐって

    第２章　病理・病態生理
    　病理 　
    　病因　
    　病態生理

    第３章　診断
    　診断の基本 　
    　画像診断 　
    　肺機能検査所見、運動耐用能試験（６分間歩行）　
    　心電図、心エコー所見 　
    　血液検査所見 　
    　気管支肺胞洗浄液所見 　
    　サルコイドーシスと鑑別されるべき疾患：
    　　（１）過敏性肺臓炎 　
    　　（２）慢性ベリリウム症 　
    　　（３）特発性肺線維症 　
    　　（4）リンパ腫/ＭＡＬＴ、膠原病 　
    　　（5）高カルシウム血症、骨粗しょう症、不明熱

    第４章　管理・治療
    　管理・治療の基本 　
    　治療薬剤
    　　（１）ステロイド薬 　
    　　（２）代替治療薬剤 　
    　　（３）そのほか：在宅酸素療法、合併症などの治療を含む
    　経過・予後

    第５章　肺外サルコイドーシス
    　眼サルコイドーシス 　
    　皮膚サルコイドーシス 　
    　Blau症候群 　
    　心サルコイドーシス 　
    　神経サルコイドーシス、全身症状　　　　
    　骨、関節、筋肉サルコイドーシス　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・定義

P.22 掲載の参考文献
1) 三上理一郎, 他:サルコイドーシス研究 100年の展望:サ症病院論の新しい仮説に向けて. 日胸臨 55:503-511, 595-610, 1996.
 
2) Hunninghake G W, et al:ATS/ERS/WA-SOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 167(2):149-173, 1999.
 
3) 日本サルコイドーシス/肉芽腫性疾患学会雑誌編集委員会 編:ATS/ERS/WASOG によるサルコイドーシスに関するステートメント. サルコイドーシス/肉芽腫性疾患217(1):97-124, 2001.
 
4) Michielsen H J, et al:Fatigue is associated with quality of life in sarcoidosis patients. Chest 1307(4):989-994, 2006.
 
5) Hoitsma E, et al:Impact of pain in a Dutch sarcoidosis patient population. Sarcoidosis Vasc Diffus Lung Dis 207(1):33-39, 2003.
 
6) Hoitsma E, et al:The small fiber neuropathy screening list:Construction and cross-validation in sarcoidosis. Respir Med 1057(1):95-100, 2011.
 
7) Ishige I, et al:Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 354:120-123, 1999.
PubMed
8) Eishi Y, et al:Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol 40:198-204, 2002.
PubMed
9) 江石義信:サルコイドーシスの病因論. サルコイドーシスとその他の肉芽腫性疾患7(安藤正幸, 他 監, 日本サルコイドーシス/肉芽腫性疾患学会 編). 36-43, 克誠堂, 東京. 2006.
 
10) Yamada Y, et al:Influence of stressful life events on the onset of sarcoidosis. Respirology 87(2):186-191, 2003.
 
11) 山口哲生, 他:サルコイドーシスにおける骨病変の臨床的検討. 日サ会誌 25:11-16, 2005.
 
12) 山口哲生, 他:上咽頭の検索が診断に有用であったサルコイドーシスの2症例. 日サ会誌 22:45-49, 2002.
 
13) Takemura T, et al:Ultrastructural features of alveolitis in sarcoidosis. Am J Respir Crit Care Med 152:360-366, 1995.
PubMed
14) Takemura T, et al:Pulmonary vascular involvement in sarcoidosis:granulomatousangi it is and microangiopathy in transbronchial lung biopsies. Virchows Archiv A. Pathol Anat 418:361-368, 1991.
PubMed
15) Mikami R, et al:Changes in the peripheral vasculature of various organs in patients with sarcoidosis-possible role of microangiopathy. Heart Vessels 2:129-139, 1986.
PubMed
16) Tolnay E, et al:Expression and localization of vascular endothelial growth factor and its receptor flt in pulmonary sarcoidosis. Virchows Arch 4327(1):61-65, 1998.
 
17) Okabe T, et al:A macrophage factor that stimulates the proliferation of vascular endothelial cells. Biochem Biophys Res Commun 1347(1):344-350, 1986.
 
18) Hiraga Y, et al:Fluorescence bronchial angiography in sarcoidosis. Ann NY Acad Sci 465:731-737, 1986.
PubMed
19) Kobayashi F:On microangiopathy of sarcoid retinopathy. Acta Soc Ophthalmol Jpn 36:452-457, 1992.
 
20) Ohara K, et al:Intraocular manifestations of systemic sarcoidosis. JPn J Ophtalmol 36:452-457, 1992.
 
21) Shimada Y, et al:Electron microscopic findings of skeletal muscles in sarcoidosis. J Clin Electron Microscopy 83:544, 1975.
 
22) 関口守衛, 他:心筋サルコイドーシスにおけるmicroangiopathy-心内膜心筋生検によって認められた基底膜多層化病変の観察-. 東女子医大誌 52:874-879, 1982.
 
23) 龍神良忠, 他:Sarcoidosisにおける腎病変-肉芽腫と糸球体病変-. 抗研誌 37:257-263, 1985.
 
24) Lacomis D:Small-fiber neuropathy. Muscle Nerve 26:173-188, 2002.
PubMed
25) Vinik A I, et al:Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. Exp Clin Endoclinol Diabetes 1097(suppl 2):S451-S473, 2001,
 
26) Morimoto T. et al:Epidemiology of sarcoidosis in Japan. Eur Respir J. 317(2):372-379, 2008.
 
27) 今野 哲, 他:北海道における臨床調査個人票に基づくサルコイドーシスの疫学調査. 厚生労働科学研究費補助金 びまん性肺疾患に関する調査研究 平成23年度報告書, 345-352, 2012.
 
28) Sasagawa S, et al:Epidemiology of sarcoidosis in:Sarcoidosis and other granulomatous disorders. Baughman RP ed. 13-46, Tayor and Fracis Group, New York, 2006.
 
P.32 掲載の参考文献
1) 細田 裕:Sarcoidologyの歴史-欧米と日本の研究の歩み-. サルコイドーシスとその他の肉芽腫性疾患7(日本サルコイドーシス/ 肉芽腫性疾患学会 編). pp1-24.克誠堂出版 東京, 2006.
 
2) 工藤翔二:JSSOG の温故知新とこれからの課題 日サ会誌 29:1, 2009.
 
3) 工藤翔二:難病克服事業とサルコイドーシス. サルコイドーシスとその他の肉芽腫性疾患7(日本サルコイドーシス/肉芽腫性疾患学会 編). pp35.克誠堂出版, 東京, 2006.
 
4) 難病情報センターホームページ.(http://www.nanbyou.or.jp)
 
5) サルコイドーシスの診断基準と診断の手引き-2006.日サ会誌 27:89-101, 2007.
 
6) 杉山幸比古監修,山口哲生, 他, 編集:肺サルコイドーシスの治療-その多様性に応じた適切な治療法を考える-, 栃木, 2012.
 

第2章 病理・病態生理

P.44 掲載の参考文献
1) Hunninghake G W, et al:ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16149-173, 1999. (同じ論文は以下にも掲載されている) Statement on sarcoidosis. Joint Statement of the American Thoracic Society(ATS), the European Respiratory Society(ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders(WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee. Am J Respir Crit Care Med 160:736-755, 1999.
 
2) サルコイドーシスの診断基準と診断の手引き-2006要約. 日サ会誌 26:77-82, 2006.
 
3) Tierstein A S, et al:The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22139-146, 2005.
 
4) Popper H H:Epithelioid cell granulomatosis of the Lung:New insights and concepts. Sarcoidosis Vasc Diffuse Lung Dis 16:32-46, 1999.
PubMed
5) Kurata A, et al:Inflamamtory cells in the formation of tumor-related sarcoid reactions. Human Pathol 36:546-554, 2005.
 
6) Rosen Y:Pathology of sarcoidosis. Semin Respir Crit Care Med 28:36-52, 2007.
PubMed
7) Hamazaki T:Uber ein neues, sauerfeste Substanz fuhrendes Spindelkorperchen der Menshlichen Lymphdrusen, Virhows Arch A Pathol Anat 301:490-522, 1938.
 
8) Wesenberg W:On acid-fast Hamazaki spindle bodies in sarcoidosis of lymph nodes and on double refractile cell inclusions in sarcoidosis of the lungs. Arch Klin Exp Dermatol 227:101-107, 1966.
 
9) Negi M, et al:Localization of Propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and bacterium. Mod Pathol 25(in press), 2012
 
10) Yamada T, et al:In situ localization of Pzropionibacterium acnes DNA in lymph nodes from sarcoidosis patients by signal amplification with catalysed reporter deposition. J Pathol 198:541-547, 2002.
PubMed
11) 松岡緑郎, 他:経気管支肺生検によるサルコイドーシス肺病変分布の検討. 日本胸疾会誌 24:1334-1338, 1986.
 
12) Takemura T, et al:Pulmonary vascular involvement in sarcoidosis:granulomatous angiitis and microangiopathy in transbronchial lung biopsies. Virchows Archiv A Pathol Anat 418:361-368, 1991.
PubMed
14) Takemura T, et al:Pulmonary vascular involvement in sarcoidosis:A report of 40 autopsy cases. Hum Pathol 23:1216-1223, 1992.
PubMed
15) Handa T, et al:Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 129:1246-1252, 2006.
PubMed
16) Corte T J, et al:Pulmonary hypertension in sarcoidosis:A review. Respirology 16:69-77, 2011.
PubMed
17) Mikami R, et al:Changes in peripheral vasculature of various organs in patients with sarcodiosis.-possible role of microangiopathy. Heart Vessels 2:129-139, 1986.
 
18) Meyers K C, et al:Studies of r lavage cells and fiuids in pulmonary sarcoidosis. I. Enhanced capacity of bronchoalveolar lavage cells from patlents with pulmonary sarcoidosis to induce angiogenesis in vivo. Am Rev Respir Dis 140:1446-1449, 1989.
 
19) Tolnay E, et al:Expression and localization of vascular endothelial growth factor and Its receptor flt in pulmonary sarcoidosis. Virchows Archiv 432:61-65, 1998.
PubMed
20) 武村民子, 他:サルコイドーシス肺における構築改変-66剖検肺の病理学的検討. 日サ会誌 23:43-52, 2003.
 
21) Shigemitsu H, et al:Chronic interstitial penumonitis in end-stage sarcoidosis. Eur Respir J 35:695-697, 2010.
 
13 Rosen Y, et al:Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 101:170-174, 1977.
PubMed
P.53 掲載の参考文献
1) Homma J Y, et al:Bacteriological investigation on biopsy specimens from patients with sarcoidosis. Jpn J Exp Med 487(3):251-255, 1978.
 
2) Abe C, et al:Frequent isolation of Propionibacterium acnes from sarcoidosis lymph nodes. Zentralbl Bakteriol Mikrobiol Hyg A 256(4):541-547, 1984.
PubMed
3) Nakata Y, et al:Alveolar lymphocyte proliferation induced by Propionibacterium acnes in sarcoidosis patients. Acta Med Okayama 40(5):257-264, 1986.
PubMed
4) 片岡幹男, 他:サルコイドーシス患者肺胞リンパ球のPropionibacterium acnesとの反応. 日サ会誌 23:23-31, 2003.
 
5) 江石義信:サルコイドーシス起因体追求の歴史と現状. 日臨 52(6):1486-1491, 1994.
Medical*Online
6) Ishige I, et al:Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 354(9173):120-123, 1999.
PubMed
7) Eishi Y, et al:Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol 177(3):198-204,2000.
 
8) Yamada T, et al:In situ localization of Propionibacterium acnes DNA in lymph nodes from sarcoidosis patients by signal amplification with catalysed reporter deposition. J Pathol 407(1):541-547, 2002.
 
9) Minami J, et al:Pulmonary granulomas caused experimentally in mice by a recombinant trigger-factor protein of Propionibacterium acnes. J Med Dent Sci 507(4):265-274, 2003.
 
10) 江石義信:サルコイドーシスの病院論的診断. 日胸(増刊) 67(11):S238-S244, 2008.
 
11) Harada K, et al:Molecular identification of bacterial 16S ribosomal RNA gene in liver tissue of primary biliary cirrhosis:is Propionibacterium acnes involved in granuloma formation? Hepatology 337(3):530-536, 2001.
 
12) 平賀洋明, 他:サルコイドーシスに対する抗生物質7(L-keflex) の二重盲検比較検討. 日サルコイドーシス会誌 77(1):103-105, 1987.
 
13) 平賀洋明, 他:サルコイドーシスに対する抗生物質の効果. 厚生省特定疾患びまん性肺疾患調査研究班平成6年度研究報告書, pp174-175, 1995.
 
14) Bachelez H, et al:The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 137(1):69-73, 2001.
PubMed
15) 岸田 猛, 他:難治性サルコイドーシスのミノサイクリン治療効果:外因に対する示唆. サルコイドーシス 24(1):43-48, 2004.
Medical*Online
16) Baba K, et al:A case of sarcoidosis with multiple endobronchial mass lesions that disappeared with antibiotics. Sarcoidosis Vasc Diffuse Lung Dis 23(1):78-79, 2006.
 
17) 山口哲生:サルコイドーシスの抗菌薬治療. 日胸67(4):309-318, 2008.
 
18) Tercelj M, et al:Antifungal treatment in sarcoidosis-a pilot intervention trial, Respir Med 101(4):774-778, 2007.
PubMed
19) 折津 愈:サルコイドーシスに対する抗菌薬使用経験(全国アンケート調査より). 厚生労働科学研究費補助金難治性疾患克服事業 びまん性肺疾患調査研究班平成16年度研究報告書, pp210-213, 2005.
 
20) Conte Jr J E, et al:Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob Agents Chemother 40(7):1617-1622, 1996.
 
21) Toutous-Trellu L, et al:Three cases of cutaneous sarcoidosis:search for bacterial agent by the 16S RNA gene analysis and treatment with antibiotics. Dermatology 200(4):342-345, 2000.
PubMed
22) Mangiapan G, et al:Mycobacteria and sarcoidosis:an overview and summary of recent molecular biological data. Sarcoidosis 12(1):20-37, 1995.
PubMed
23) Song Z, et al:Mycobacterial catalase-peroxidase is a tissue antigen and target ofthe adaptive immune response in systemic sarcoidosis. J Exp Med 201(5):755-767, 2005.
 
24) Chen ES, et al:T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic saecoidosis. J Immunol 181(12):8784-8796, 2008.
PubMed
25) Wiken M, et al:Antigen-specific multifunctional T cells in sarcoidosis patients with Lofgren's syndrome. Eur Respir J 2011.(Epub ahead of print)
 
P.61 掲載の参考文献
1) Morgenthau A S, et al:Recent advances in sarcoidosis. Chest 139:174-182, 2011.
PubMed
2) Iannuzzi M C, et al:Sarcoidosis. N Engl J Med 357:2153-2165, 2007.
PubMed
3) Chen ES, et al:Sarcoidosis-scientificprogress and clinical challenges. Nat Rev Rheumatol 7:457-467, 2011.
PubMed
4) Inui N, et al:TH1/TH2 and TC1/TC2 profiles in peripheral blood and bronchoalveolar lavage fluid cells in pulmonary sarcoidosis. J Allergy Clin Immunol 107:337-344, 2001.
PubMed
5) Nishioka Y, et al:CXCL9 and 11 in patients with pulmonary sarcoidosis:a role of alveolar macrophages. Clin Exp Immunol 149:317-326, 2007.
PubMed
6) Kishi J, et al:Blockade of Th1 chemokinereceptors ameliorates pulmonary granulomatosis in mice. Eur Respir 38:415-424, 2011.
 
7) Baughman R P, et al:Infliximab therapy inpatients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174:795-802, 2006.
 
8) Massara A, et al:Sarcoidosis appearing during anti-tumor necrosis factor alphatherapy:a new "class effect"paradoxicalphenomenon. Two case reports and literature review. Sem Arthritis Rheum 39:313-319, 2010.
 
9) Veltkamp M, et al:Linkage between Toll-like receptor (TLR)2 promotor and intronpolymorphisms:functional effects and relevance to sarcoidosis. Clin Exp Immunol 149:453-462, 2007.
 
10) Rastogi R, et al:Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells. Am J Respir Crit Care Med 183:500-510, 2011.
PubMed
11) Ehrt S, et al:Reprogramming of the macrophage transcriptome in response tointerferon-gamma and Mycobacterium tuberculosis:signaling roles of nitric oxidesynthase-2 and phagocyte oxidase. J Exp Med 194:1123-1140, 2001.
 
12) Chen E S, et al:Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2.Am J Respir Crit Care Med 181:360-373, 2010.
PubMed
13) Tanabe T, et al:Sarcoidosis and NOD1 variation with impaired recognition of intracellular Propionibacterium acnes. Biochim Biophy Acta 1762:794-801, 2006.
PubMed
14) Fireman E, et al:Induced sputum-retrieved matrix metalloproteinase 9 and tissue metalloproteinase inhibitor 1 in granulomatous diseases. Clin Exp Immunol 130:331-337, 2002.
PubMed
15) Prasse A, et al:A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 173:781-792, 2006.
 
16) Shirai M, et al:The influence of ovarian hormones on the granulomatous inflammatory process in the rat lung. Eur Resp J 8:272-277, 1995.
 
17) Chida K, et al:Successful treatment of hepatic sarcoidosis with hormone replacement in a postmenopausal woman. Respirology 4:259-261, 1999.
 
18) Yamada Y, et al:Influence of stressful life events on the onset of sarcoidosis. Respirology 8:186-191, 2003.
PubMed
19) Statement on sarcoidosis. Joint Statementof the American Thoracic Society (ATS), the European Respiratory Society(ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Resp Crit Care Med 160:736-755, 1999.
 
20) Inui N, et al:Anti-endothelial cell antibodies in patients with sarcoidosis. Chest 133:955-960, 2008
PubMed

第3章 診断

P.73 掲載の参考文献
1) 泉 孝英:サルコイドーシスの臨床像. サルコイドーシスとその他の肉芽腫性疾患7(安藤正幸, 他 監), p26-34, 克誠堂出版, 東京, 2006.
 
2) Morimoto T, et al:Epidemiology of sarcoidosis in Japan. Eur Respir J 31(2):372-379, 2008.
PubMed
3) びまん性肺疾患調査研究班:サルコイドーシス. 難病の診断と治療方針7(厚生省保険医療局疾病対策課監修, 難病医学研究財団企画委員会 編), p62-71. 1997.
 
4) サルコイドーシスの診断基準と診断の手引き-2006. 日サ会誌 27:89, 2007.
 
5) 長井苑子:サルコイドーシス, 日常診療の手引き呼吸器疾患7(清水喜八郎, 他 監編),p135-140.臨床医薬研究協会, 東京, 2002.
 
6) 山口哲生:サルコイドーシスの外来診療. 呼吸器内科 187(2):135-142, 2010.
 
7) Uemura A, et al:Histologic diagnostic rate of cardiac sarcoidosis:evaluation of endomyocardial biopsies. Am Heart J 138(2 Pt 1):299-302, 1999.
 
8) Yoshida Y, et al:Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J 134(3):382-386, 1997.
PubMed
P.81 掲載の参考文献
1) Koyama T, et al:Radiologic manifestations of sarcoidosis in various organs. Radiographics 24(1):87-104, 2004.
PubMed
2) サルコイドーシス診断基準改訂委員会:サルコイドーシスの診断基準と診断の手引き-2006. サルコイドーシス/肉芽腫性疾患 27(1):89-102, 2007.
 
3) Webb W R, et al:Sarcoidosis. In:High-Resolution CT of the Lung, 4th Edition, p273-300. Lippincott Williams & Wilkins, New York, 2008
 
P.87 掲載の参考文献
1) Statement on sarcoidosis. Joint Statement of the American Thoracic Society(ATS), the European Respiratory Society(ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders(WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am Respir Crit Care Med 160:736-755, 1999.
PubMed
2) 泉 孝英:サルコイドーシスの国際比較-臨床象・病理像-. 別冊・医学のあゆみ サルコイドーシス診療と研究の最新動向 p9-49, 1997.
 
3) 武村民子:サルコイドーシスの病理像,サルコイドーシスとその他の肉芽腫性疾患(日本サルコイドーシス/肉芽腫性疾患学会 編) p52-62. 2006.
 
4) Bergin C J, et al:Sarcoidosis:correlation of pulmonary parenchymal pattern at CT with results of pulmonary function tests. Radiolory 171:619-624, 1989.
 
5) Sharma O P, et al:Airway obstruction in sarcoidosis. A study of 123 nonsmoking black American patients with sarcoidosis. Chest 94:343-346, 1988.
PubMed
6) Sims H S, et al:Airway involvement and obstruction from granulomas in African-American patients with sarcoidosis. Respir Med 101:2279-2283, 2007.
PubMed
7) Lavergne F, et al:Airway obstruction in bronchial sarcoidosis:outcome with treatment. Chest 116:1194-1199, 1999.
PubMed
8) Naccache J M, et al:High-resolution computed tomographic imaging of airways in sarcoidosis patients with airflow obstructlon. Comput Assist Tomogr 32:905-912, 2008.
PubMed
9) Hansell D M, et al:Pulmonary sarcoidosis:morphologic associations of airflow obstruction at thin-section CT. Radiology 209:697-704, 1998.
PubMed
10) Medinger A E, et al:Sarcoidosis:the value of exerclse testing. Chest 120:93-101, 2001.
 
11) Lamberto C, et al:Membrane and capillary blood components of diffusion capacity of the lung for carbon monoxide in pulmonary sarcoidosis:relation to exercise gas exchange. Chest 125:2061-2068, 2004.
PubMed
12) Phansalkar A R, et al:Nitric oxide diffusing capacity and alveolar microvascular recruitment in sarcoidosis. Am J Respir Crit Care Med 169:1034-1040, 2004.
PubMed
13) Handa T, et al:Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 129:1246-1252, 2006.
PubMed
14) Hamada K, et al:Significance of Pulmonary Arterial Pressure and Diffusion Capacity of the Lung as Prognosticator in Patients with Idiopathic Pulmonary Fibrosis. Chest 131:650-656, 2007.
PubMed
15) Baughman R P, et al:Survival in sarcoidosis-associated pulmonary hypertension:the importance of hemodynamic evaluation. Chest 138:1078-1085, 2010.
PubMed
16) Furuya K, et al:Angiotensin-I-converting enzyme gene polymorphism and susceptibility to cough. Lancet 343:354, 1994
PubMed
17) Niimi T, et al Bronchial responsiveness and angiotensin-converting enzyme gene polymorphism in sarcoidosis patients. Chest 114:495-499 1998
PubMed
18) 佐伯幸子, 他:気管支喘息とサルコイドーシスを合併した症例の臨床的検討. 日呼吸会誌 41:777-780, 2003.
Medical*Online
19) Wilsher M et al:Prevalence of asthma and atopy in sarcoidosis. Respirology 17:285-290, 2012.
PubMed
20) Chol J, et al:Multiple flow rates measurement of exhaled nitric oxide in patients with sarcoidosis:a pilot feasibility study. Sarcoidosis Vasc Diffuse Lung Dis 26:98-109, 2009.
 
21) Wilsher M L, et al:Exhaled nitric oxide in sarcoidosis. Thorax 60:967-970, 2005.
PubMed
22) Spruit M A, et al:Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax 60:32-38, 2005.
PubMed
23) Marcellis R G, et al:Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 38:628-634, 2011.
PubMed
24) Brancaleone P, et al:Clinical impact of inspiratory muscle impairment in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 21:219-227, 2004.
PubMed
25) Kabitz H J, et al:Impact of impaired inspiratory muscle strength on dyspnea and walking capacity in sarcoidosis. Chest 130:1496-1502, 2006
PubMed
26) Baughman R P, et al:Six-minute walk test and health status assessment in sarcoidosis. Chest 132:207-213, 2007.
PubMed
27) Wallaert B, et al:Reduction of maximal oxygen uptake in sarcoidosis:relationship with disease severity. Respiration 82:501-508, 2011.
PubMed
28) Lopes A J, et al:Comparison between cardiopulmonary exercise testing parameters and computed tomography findings in patients with thoracic sarcoidosis. Lung 189:425-431, 2011.
PubMed
P.98 掲載の参考文献
1) Hunnighake G W, et al:ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16(2):149-173, 1999.
 
2) Iwai K, et al:Racial difference in cardiac sarcoidosis incidence obderved at autopsy. Sarcoidosis 11(1):26-31, 1994.
 
3) Doughan A R, et al:Cardiac sarcoidosis. Heart 92(2):282-288, 2006.
PubMed
4) Iwai K, et al:Pathological studies on sarcoidosis autopsy. I. Epidemiological features of 320 cases in Japan. Acta Pathol Jpn 437(7-8):372-376, 1993
 
5) Kato Y, et al:Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis 20(2):133-137, 2003.
PubMed
6) Yazaki Y, et al:Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 887(9):1006-1010, 2001.
 
7) Yoshida Y, et al:Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J 1347(3):382-386, 1997.
 
8) 加藤靖周:診断の手引きを満たさないものの強く心臓サルコイドーシスが疑われた2症例. 日サ会誌 19(1):91-96, 1999.
 
9) Roberts W C, et al:Sarcoidosis of the heart. A clinicopathologic study of 35 necropsypatients (group I) and review of 78 previously described necropsy patients (group II), Am J Med 63(1):86-108, 1977.
 
10) Valantine H, et al:Sarcoidosis. A pattern of clinical and morphological presentation. Br Heart J 57(3):256-263, 1987.
PubMed
11) Morimoto S, et al:A proposal for diagnostic criteria of basal thinning of the interventricular septum in cardiac sarcoidosis (CS). A multicenter study. Circ J 70(Suppl I):215, 2005.
 
12) Uemura A, et al:Relationship between basal thinning of the interventricular septum and atrioventricular block in patients with cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 22(1):63-65, 2005.
PubMed
13) Otsuka K, et al:Cardiac sarcoidosis underlies idiopathic dilated cardiomyopathy. Importance of mediastinal lymphadenopathyin differential diagnosis. Circ J 71(12):1937-1941, 2007.
 
14) Uemura A, et al:Histologic diagnostic rate of cariac sarcoidosis. Evaluation of endomyocardial biopsies. Am Heart J 138(2):299-302, 1999.
 
15) Cross B, et al:Cardiac sarcoidosis presenting as mitral regurgitation. J Am Soc Echocardiogr 20(7):906:9-13, 2007.
 
16) Yazaki Y, et al:Cardiac sarcoidosis mimicking hypertrophic cardiomyopathy. Clinical utility of radionuclide imaging for differential diagnosis. Jpn Circ J 62(6):465-468, 1998.
PubMed
17) Matsumori A, et al:Hypertrophic cardiomyopathy as a manifestation of cardiacsarcoidosis. Jpn Circ J 64(9):679-683, 2000.
PubMed
18) Kosuge H, et al:Left ventricular apicalaneurysm in cardiac sarcoidosis. Jpn Heart J 427(2):265-269, 2001.
 
19) Jain A et al:Ventricular tachycardia andventricular aneurysm due to unrecognized sarcoidosis. Clin Cardiol 13:738-740, 1990.
PubMed
P.107 掲載の参考文献
1) Hunninghake G W, et al:ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 16(2):149-173, 1999.
PubMed
2) 日本サルコイドーシス/肉芽腫性疾患学会サルコイドーシスの診断基準と診断の手引き-2006 要約. 日サルコイドーシス肉芽腫会誌 26:77-82, 2006.
 
3) Lieberman J:Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis. Am J Med 597(3):365-372, 1975.
 
4) Hinman L M, et al:Angiotensin convertase activities in human alveolar macrophages:effects of cigarette smoking and sarcoidosis. Science 205(4402):202-203, 1979.
PubMed
5) Silverstein E, et al:Immunofluorescent localization of angiotensin converting enzyme in epithelioid and giant cells of sarcoidosis granulomas. Proc Natl Acad Sci USA 76(12):6646-6648, 1979.
PubMed
6) Lieberman J, et al:Clinical correlations of serum angiotensin-converting enzyme (ACE) in sarcoidosis. A longitudinal study of serum ACE, 67gallium scans, chest roentgenograms, and pulmonary function. Chest 84(5):522-528, 1983.
PubMed
7) 山本正彦:サルコイドーシスの臨床. 日内会誌 76(10):1497-1514, 1987.
 
8) Tomita H, et al:Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med 156(1):255-259, 1997.
PubMed
9) 四十坊典晴, 他:類上皮細胞肉芽腫を証明したサルコイドーシス516例における各種検査所見の解析. サルコイドーシス 277(1):29-35, 2007.
 
10) Costabel U, et al:Biochemical changes in sarcoidosis. Clin Chest Med 18(4):827-842, 1997.
PubMed
11) Kasahara Y, et al:Colorimetry of angiotensin-I converting enzyme activity in serum. Clin Chem 27(11):1922-1925, 1981.
PubMed
12) Rigat B, et al:An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86(4):1343-1346, 1990.
PubMed
13) 新美岳:ビタミンDレセプター遺伝子多型がサルコイドーシスに与える影響の研究. 名古屋市大医会誌 507(3):133-140, 1999.
 
14) Hamada K, et al:Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. Eur Respir J 11(5):1015-1020, 1998.
PubMed
15) 立花暉夫:第3章サルコイドーシスの臓器病変5肝臓・脾臓・消化器. サルコイドーシスとその他の肉芽腫性疾患7(日本サルコイドーシス/肉芽腫性疾患学会編) p94-101. 克誠堂出版,東京, 2006.
 
16) 片岡幹男, 他:間質性肺疾患の単球・マクロファージの動態と活性化. 日臨免疫会誌 127(5)537-543, 1989.
 
17) Pascual RS, et al:Usefulness of serum lysozyme measurement in diagnosis and evaluation of sarcoidosis. N Engl J Med 289(20):1074-1076, 1973.
PubMed
18) 森下宗彦, 他:サルコイドーシス患者の血清リゾチーム活性. 日胸疾患会誌 15:509-514, 1977.
 
19) 鳥井義夫, 他:血清アンジオテンシン変換酵素活性と血清リゾチーム活性についてサルコイドーシスおよび各肉芽腫性肺疾患を中心に. 日胸疾患会誌 19:111-121, 1981.
 
20) Tomita H, et al:Serum lysozyme levels and clinical features of sarcoidosis. Lung 177(3):161-167, 1999.
PubMed
21) Veien N K, et al:Immunological studies in sarcoidosis:a comparison of disease activity and various immunological parameters. An N Y Acad Sci 278:47-51, 1976.
 
22) Lawrence E C, et al:Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fiuids in active sarcoidosis. Am Rev Respir Dis 137(4):759-764, 1988.
PubMed
23) Ina Y, et al:Soluble interleukin 2 receptors in patients with sarcoidosis, Possible origin. Chest 102(4):1128-1133, 1992.
PubMed
24) Kobayashi J, et al:Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest 109(5):1276-1282, 1996.
PubMed
25) Miyoshi S, et al:Comparative evaluation of serum markers in pulmonary sarcoidosis, Chest 137(6):1391-1397, 2010.
PubMed
P.118 掲載の参考文献
1) Reynolds H Y, et al:Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med 84(4):559-573, 1974.
PubMed
2) 米田良蔵:BAL法の手技. 気管支肺胞洗浄[BAL]法の臨床ガイドライン.7(田村昌士 監). p14-27, 克誠堂, 東京, 1995.
 
3) Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. BAL Cooperative Group Steering Committee. Am Rev Respir Dis 141(5 Pt2):S169-202, 1990.
 
4) Welker L, et al:Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J 24(6):1000-1006, 2004.
PubMed
5) 半田知宏:II. 各疾患のBAL所見, B. 間質性肺炎, 3.サルコイドーシス. 気管支肺胞洗浄[BAL]法の手引き.7(日本呼吸器学会びまん性肺疾患学術部会・厚労省難治性疾患克服研究事業びまん性肺疾患調査研究班監). p73-76, 克誠堂, 東京, 2008.
 
6) Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 160(2):736-755, 1999.
PubMed
7) Iannuzzi M C, et al:Sarcoidosis. N Engl J Med 357(21):2153-2165, 2007.
PubMed
8) Wahlstrom J, et al:Analysis of intracellularcytokines in CD4+ and CD8+ lung and blood T cells in sarcoidosis. Am J Respir Crit Care Med 163(1):115-121, 2001.
 
9) Costabel U:Sensitivity and sepcificity of BAL findings in sarcoidosis. Sarcoidosis 9 (Supply 1):211-214, 1992.
 
10) Winterbauer R H, et al:Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 104(2):352-361, 1993.
PubMed
11) サルコイドーシスの診断基準と診断の手引き-2006. 日サル会誌 277(1):89-102, 2007.
 
12) Keogh BA, et al:The alveolitis of pulmonary sarcoidosis. Evaluation of natural history and alveolitis-dependent changes in lung function. Am Rev Respir Dis 128(2):256-265, 1983.
PubMed
13) Foley N M, et al:Bronchoalveolar lavage cell counts as a predictor of short term outcome in pulmonary sarcoidosis. Thorax 44(9):732-738, 1989.
PubMed
14) Costabel U, et al:Predictive value of bronchoalveolar T cell subsets for the course of pulmonary sarcoidosis. Ann N Y Acad Sci 465:418-426, 1986.
PubMed
15) Verstraeten A, et al:Predictive value of bronchoalveolar lavage in pulmonary sarcoidosis. Chest 98(3):560-567, 1990.
PubMed
P.125 掲載の参考文献
1) Suga M, et al:Mechanisms accounting for granulomatous responses in hypersensitivity pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis 14:131-138, 1997.
PubMed
2) 安藤正幸:過敏性肺臓炎. 日本臨床別冊 領域別症候群シリ-ズ No.3 呼吸器症候群上巻 p418-423. 日本臨床社, 大阪, 1994.
 
3) 長井苑子:間質性肺疾患の外来診療. p79-81, 医学書院, 東京, 2010.
 
4) Ohtani Y, et al:Chronic bird fancier's lung:histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 60:665-671, 2005.
PubMed
5) 井上哲郎, 他:鳥関連慢性過敏性肺炎8例の臨床的検討. 日呼吸会誌 44:550-554, 2006.
Medical*Online
6) Ando M, et al:Japanese summer-type hypersensitivity pneumonitis. Geographic distribution, home environment, and clinical characteristics of 621 cases. Am Rev Respir Dis 144:765-769, 1991.
PubMed
7) Lynch D A, et al:Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis? AJR Am J Roentgenol 165:807-811, 1995.
PubMed
8) Cook PG et al:The distribution of pulmonary shadowing in farmer's lung. Clin Radiol 39:21-27, 1988.
PubMed
9) Kokkarinen J I, et al:Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung Am Rev Respir Dis 145:3-5, 1992
PubMed
10) Perez-Padilla R, et al:Mortality in Mexican patients with chronic pigeon breeder's lung compared with those with usual interstitial pneumonia. Am Rev Respir Dis 148:49-53, 1993.
PubMed
P.130 掲載の参考文献
1) Handa T, et al:Long-term complicationsand prognosis of chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 26:24-31, 2009.
 
2) Izumi T, et al:The first seven cases ofchronic beryllium disease in ceramic factory workers in Japan. Ann NY Acad Sci 278:636-653, 1976.
 
3) Van Dyke M V, et al:Risk of chronic beryllium disease by HLA-DPBI E69 genotypeand beryllium exposure in nuclear workers. Am J Respir Crit Care Med 183:1680-1688, 2011.
 
4) 長井苑子:間質性肺疾患の外来診療. p105-106. 医学書院, 東京, 2010.
 
5) Cummings K J, et al:Enhanced preventive programme at a beryllium oxide ceramics facility reduces beryllium sensitisation among new workers. Occup Environ Med 64:134-140, 2007.
 
6) Newman L S, et al:Interstitial lung disorders due to beryllium and cobalt. In:Interstitial lung disease, 3rd ed. (Schwarz MI, et al, eds). p367-392. BC Decker, Hamilton, London, 1998.
 
7) Newman L S:Beryllium disease and sarcoidosis:clinical and laboratory links. Sarcoidosis 12:7-19, 1995.
PubMed
8) Handa T, et al:Clinical and radiographic indices associated with airflow limitation in patients with sarcoidosis. Chest 130:1851-1856, 2006.
PubMed
9) 北市正則:サルコイドージス, 慢性ベリリウム肺および過敏性肺臓炎の肺病変の病理組織学的比較検討. 日胸疾会誌 22:769-781, 1984.
 
10) Hardy H L, et al:Delayed chemical pneumonitis occurring in workers exposed to beryllium compounds. J Ind Hyg Toxicol 28:197-211, 1946.
PubMed
P.141 掲載の参考文献
1) Akira M, et al:Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosi& Chest 127(1):185-191, 2005.
 
2) Tachibana K, et al:A case of combined sarcoidosis and usual interstitial pneumonia. Inter Med 2012(in press)
 
3) Raghu G, et al:ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 1837(6):788-824, 2011.
 
4) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作製委員会:特発性間質性肺炎診断と治療の手引き改訂2版. 南江堂, 東京, 2011.
 
5) Crystal R G, et al:Idiopathic pulmonary fibrosis. Clinical, histological, radiographic, physiologic, and biochemical aspects. Ann Intern Med 85:769-788, 1976.
PubMed
6) King T E, et al:Idiopathic pulmonary fibrosis:Diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161:646-664, 2000.
 
7) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am Respir Crit Care Med 165:277-304, 2002
 
8) 本間行彦:病名の一致について. 厚生省特定疾患間質性肺疾患調査研究班昭和55年度研究報告書 1980:3.
 
9) 本間行彦, 他:特発性間質性肺炎7(IIP) の臨床診断基準:第3次改定案. 厚生省特定疾患間質性肺疾患調査研究班. 平成3年度研究報告書. 1991:20.
 
10) Akira M, et al:Usual interstitial pneumonia and nonspecific interstitial pneumonia with and without concurrent emphysema:thin-section CT findings. Radiology 251(1):271-279, 2009.
PubMed
11) Webb W R, et al:High-resolution CT of the lung 3rd ed. pp.193-354. Lippincott Williams & Wilkins, Philadelphia, PA, 2001.
 
12) Padley S P, et al:Pulmonary sarcoidosis mimicking cryptagenic fibrosing alveolitis on CT. Clin Radiol 51:807-810, 1996.
 
13) Hunninghake G W, et al:ATS/ERS/WA-SOG statement of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16:149-173, 1999.
 
P.149 掲載の参考文献
1) Isaacson P G, et al:Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type B-cell lymphoma. Cancer 52:1410-1416, 1983.
 
2) Ahmed S, et al:Bronchial-associated lymphoid tissue lymohoma:a clinical study of a rare disease. Eur J Cancer 40:1320-1326, 2004.
 
3) King LJ, et al:Pulmonary MALT lymphoma:imaging findings in 24 cases. Eur Radiol 10:1932-1938, 2000.
PubMed
4) Nakatsu M, et al:Large coalescent parenchymal nodules in pulmonary sarcoidosis:"sarcoid galaxy" sign. Am J Roentgenol 178:1389-1393, 2002.
 
5) Brincker H:Sarcoid reactions in malignant tumors. Cancer Treat Rev 13:147-156, 1986.
PubMed
6) Romer F:Sarcoidosis and cancer. In:Sarcoidosis and Other Granulomatous Disorders (James J, eds), p401-415.Marcel Dekker, New York, 1994.
 
7) 安東 優, 他:非乾酪性類上皮細胞肉芽腫を伴ったポジキンリンパ腫の1例. 日サ会誌 27:75-79, 2007.
 
8) Israel H L, et al:Whole-body Gallium 67 scans. Role in diagnosis of sarcoidosis. Am Rev Respir Dis 144:1182-1186, 1991.
PubMed
9) Kaira K, et al:Diagnostic usefulness of florine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 131(4):1019-1027, 2007.
 
10) 田村厚久, 他:ブドウ膜炎で発症ACE高値を示し, サルコイドーシスが疑われた, いわゆるLennertリンパ腫の1例. 日胸疾会誌 22:1033-1039, 1984.
 
11) Lawrence E C, et al:Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis. Am Rev Respir Dis 137:759-764, 1988.
PubMed
12) 田原佐知子, 他:ぶどう膜炎と血清 ACE 高値からサルコイドーシスが疑われた末梢性 T細胞リンパ腫の一剖検例. 日サルコイドーシス肉芽腫会誌 24:77-82, 2004.
 
13) Brincker H:The sarcoidosis-lymphoma syndrome. Br J Cancer 54:467-473, 1986.
PubMed
14) 森 秀法, 他:椎体破壊を伴った Sarcoidosis-Lymphoma Syndrome の1例. 日呼吸会誌 477(11):1057-1061, 2009.
 
15) 京樂由佳, 他:サルコイドーシスの経過中にポジキンリンパ腫を合併した1例. 日呼吸会誌 477(10):900-905, 2009.
 
16) 立花暉夫:サルコイドーシスの全国臨床統計. 日臨 527(6):1508-1514, 1994.
 
17) Sato T, et al:Sarcoidosis with acute recurrent polyarthritis and hypercalcemia. Intern Med 45(6):363-368, 2006.
PubMed
18) 福家 聡, 他:一次性Sjogren症候群を合併したサルコイドーシスの1例-文献例の集計も含めて-. 日呼吸会誌 40:686-691, 2002.
 
19) 磯部 全, 他:HLA-DR8陽性を示し, 多発性筋炎, シェーグレン症候群にサルコイドーシスを合併した1例. 日呼吸会誌 46(2):96-100, 2008.
Medical*Online
20) Enzenauer R J, et al:Sarcoidosis in autoimmune disease. Semin Arthritis Rheum 22(1):1-17, 1992.
PubMed
P.155 掲載の参考文献
1) Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Statement on sarcoidosis. Am J Respir Crit Care Med 160:736-755, 1999.
PubMed
2) Sharma O P:Vitamin D, calcium, and sarcoidosis. Chest 109(2):535-539, 1996.
PubMed
3) Rizzato G:Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax 53:425-429, 1998.
PubMed
4) Alberts C, et al:Calcium metabolism in sarcoidosis. A follow-up study with respect to parathyroid hormone and vitamin D metabolites. Eur J Respir Dis 68:186-194, 1986.
PubMed
5) Adams J S, et al:Biochemical indicators of disordered vitamin D and calcium homeostasis in sarcoidosis. Sarcoidosis 3:1-6, 1986.
PubMed
6) Hamada K, et al:Ionized calcium and 1, 25-dihydroxyvitamin D concentration inserum of patients with sarcoidosis. Eur Respir J 11:1015-1120, 1998.
 
7) Kavathia D, et al:Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med 104:564-570, 2010.
PubMed
8) Zeimer H J, et al:Parathyroid-hormone-related protein in sarcoidosis. Am J Pathol 152:17-21, 1998,
PubMed
9) James D G, et al:A worldwide review of sarcoidosis. Ann NY Acad Sci 278:321-334, 1976.
PubMed
10) Baughman R P, et al:Case Control Etiologic Study of Sarcoidosis (ACCESS) research group. Clinical characteristics of patients inacase control study of sarcoidosis. Am J Respir Crit Care Med 164:1885-1889, 2001.
 
11) McCurley T, et al:Renal insufficiency insarcoidosis. A clinical and pathologic study. Arch Pathol Lab Med 114:488-492, 1990.
PubMed
12) Rizzato G, et al:Nephrolithiasis as a presenting feature of chronic sarcoidosis:a prospective study. Sarcoidosis Vasc Diffuse Lung Dis 13:167-172, 1996.
PubMed
13) Hamada K, et al:Serum concentrations of ionized calcium reflect renal functions in patients with sarcoldosis. Sarcoldosis Vasc Diffuse Lung Dis 19:71-77, 2002.
 
14) Montemurro L, et al:Bone loss in untreated longstanding sarcoidosls. Sarcoldosis 8:29-34, 1991.
 
15) Sipahi S, et al:Bone minera density in women with sarcoidosis. J Bone Miner Metab 22:48-52, 2004.
 
16) Hamada K, et al:Bone mineral density and vitamin D in patients with sarcoldosis. Sarcoidosis Vasc Diffuse Lung Dis 16:219-223, 1999.
 
17) Heijckmann A C, et al:Bone turnover and hip bone mineral density in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 24:51-58, 2007.
PubMed

第4章 管理・治療

P.164 掲載の参考文献
1) 日本サルコイドーシス/肉芽腫性疾患学会, 他:サルコイドーシス治療に関する見解-2003. 日サ会誌 23:105-114, 2003.
 
2) 山口哲生:サルコイドーシスの病因・病態・診断・治療に関する疫学的並びに臨床的研究. 日サ会誌 29:3-7, 2009.
 
3) Smellie H, et al:The natural history of pulmonary sarcoidosis. Q J Med 29:539-558, 1960.
 
4) James D G:Course and prognosis of sarcoidosis. Am Rev Respir Dis 847(part 2):66-70, 1961.
 
5) Yamamoto M, et al:Factors affecting the course of sarcoidosis. In:Sarcoidosis (Japan Medical Reseach Foundation, ed).p273-284. University of Tokyo Press,Tokyo, 1981.
 
6) Hunninghake G W, et al:Outcome of treatment for sarcoidosis. Am J Respir Crit Care Med 149:893-898, 1994.
PubMed
7) Martinez F J, et al:Recurrence of sarcoidosis following bilateral allogeneic lung transplantation. Chest 106:1597-1599, 1994.
PubMed
8) James D G, et al:Treatment of Sarcoidosis:report of a controlled therapeutic trial Lancet 2:526-528, 1967.
PubMed
9) Yamamoto M, et al:Effect of 18 month corticosteroid therapy on stage I and stage II sarcoidosis patients (a control trial). In:Sarcoidosis and other Granulomatous Disorders (Chretien J, et al, eds). p470-474. Pergamon Press, Paris, 1983.
 
10) Siltzbach L E, et al:Course and prognosis of sarcoidosis around the world. Am J Med 57:847-852, 1974.
PubMed
11) Takada K, et al:The clinical course and prognosis of patients with severe, moderate or mild sarcoidois. J Clin Epidemiol 46:359-366, 1993.
PubMed
12) Gottlieb J E, et al:Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 111:623-631, 1997.
PubMed
13) Johns C J, et al:The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine 78:65-111, 1999.
 
14) Yoshida Y, et al:Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J 134:382-386, 1997.
PubMed
15) 加藤靖周, 他:心臓サルコイドーシスにおける房室伝導障害. 日サ会誌 31:66-72, 2011.
 
16) 吾妻安良太:びまん性肺疾患, 特にサルコイドーシスの病因・病態ならびに疫学研究. 日サ会誌 28:3-7, 2008.
 
P.170 掲載の参考文献
1) Paramothayan N S, et al:Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 18 CDO01114, 2005.
 
2) Hunning G W, et al:ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 16:149-173, 1999.
 
3) Mikami R, et al:A double-blind controlled trial on the effects of corticosteroid therapy in sarcoidosis. In:Proceedings of the IV International Conference on Sarcoidosis (Iwai R, et al, eds). p533-53 & University of Tokyo Press, Tokyo, 1974.
 
4) Izumi T:Are corticosteroids harmful to sarcoidosis-A conclusion drawn from a retrospective study o the chest radiograph prognosis of 185 asymptomatic patients with pulmonary sarcoidosis followed up for more than ten years. Sarcoidosis 11 (supplement I):119-122, 1994.
 
5) サルコイドーシス治療に関する見解-2003. 日サ会誌 23:105-114, 2003.
 
6) DuBois R M, et al:Randomized trial of inhaled fiuticasone proprionate in chronic stable pulmonary sarcoidosis. Eur Respir J 13:1345-1350, 1999.
 
7) Baughman R P, et al:Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 19:198-204, 2002.
 
8) Alberts C, et al:Inhaled budesonide in pulmonary sarcoidosis:a double-blind, placebo-controlled study. Eur Respir J 5:682-688, 1995.
PubMed
9) Pietinalho A, et al:Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis:adouble-blind, placebo-controlled multicenter study. Chest 116:424-431,1999.
 
10) Milman N, et al:No effect of high-dose inhaled steroids in pulmonary sarcoidosis:a double-blind, placebo-controlled study.J Intern Med 236:285-290,1994.
PubMed
11) Ohno S, et al:Inhaled corticosteroid rapidly improved pulmonary sarcoidosis. Internal Med 44:1276-1279,2005.
 
12) Niimi T, et al:Bronchial responsiveness and angiotensin-converting enzyme gene polymorphism in sarcoidosis patients. Chest 114:495-499,1998.
PubMed
P.178 掲載の参考文献
1) 四十坊典晴, 他:臨床所見, 自然経過および治療反応性に基づくサルコイドーシスの臨床型. 日サ会誌 27:21-28, 2007.
 
2) Hunninghake G W, et al:ATS/ERS/WA-SOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 16:149-173, 1999.
 
3) 日本サルコイドーシス/肉眼腫性疾患学会, 日本呼吸器学会, 日本心臓病学会, 日本眼科学会, 厚生省科学研究-特定疾患対策事業-びまん性肺疾患研究班:サルコイドーシス治療に関する見解-2003. 日サ会 23:105-114, 2003.
 
4) Baughman R P, et al:A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 183(5):573-581, 2011.
PubMed
5) Lazar C A, et al:Treatment of sarcoidosis. Semin Respir Crit Care Med 31(4):501-518, 2010.
PubMed
6) 平賀洋明:サルコイドーシスの臨床. 日サ会誌 23:33-41, 2003.
 
7) Schutt A C, et al:Pharmacotherapy for pulmonary sarcoidosis:a Delphi consensus study. Respir Med 104(5):717-723, 2010.
PubMed
8) Kiltz U, et al:Use of methotrexate in patients with sarcoidosis. Clin Exp Rheumatol 287(5 Suppl 61):S183-S185, 2010.
 
9) Baughman R P, et al:A clinical approach to the use of methotrexate for sarcoidosis. Thorax 547(8):742-746, 1999.
 
10) Baughman R P, et al:Methotrexate is steroid sparing in acute sarcoidosis:results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 17:60-66, 2000.
PubMed
11) 加藤靖周, 他:メトトレキサート療法をこころみた心臓サルコイドーシスの4症例. 日サ会誌 23:83-86, 2003.
 
12) 田中健介, 他:メトトレキサートの単剤治療が有効であったサルコイドーシスの2症例. 日サ会誌 30:9-13, 2010.
 
13) 日本リウマチ学会 MTX 診療ガイドライン策定小委員会編:関節リウマチ治療におけるメトトレキサート7(MTX) 診療ガイドライン2011年版. 羊土社, 東京, 2011.
 
14) Cottin V:Update on bioagent therapy in sarcoidosis. F1000 Med Rep 24(2):pii:13, 2010.
 
15) Baughman R P, et al:Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 74(7):795-802, 2006.
 
16) Judson M A, et al:Efficacy of infliximab in extrapulmonary sarcoidosis:results from a randomised trial. Eur Respir J 31(6):1189-1196, 2008.
PubMed
17) Baughman RP, et al:Treatment of sarcoidosis. Clin Chest Med 29(3):533-548, 2008.
PubMed
18) Paramothayan S, et al:Treatments fbr pulmonary sarcoidosis. Respir Med 102(1):1-9, 2008.
 
19) 山口哲生, 他:テトラサイクリンによるサルコイドーシスの治療. 日サ会誌 28:41-48, 2008.
 
20) Murakami K, et al:Rapid improvement of osseous sarcoidosis after the treatment of pulmonary aspergillosis by itraconazole. Sarcoidosis Vasc Diffuse Lung Dis 287(1):75-78, 2011.
 
P.186 掲載の参考文献
1) 長井苑子:サルコイドーシスの予後と合併症, サルコイドーシスとその他の肉芽腫性肺疾患(四元秀毅, 他 監修)p182-188. 克誠堂出版, 東京, 2006.
 
2) Nardi A, et al:Stage IV sarcoidosis:comparison of survival with the general population and causes of death. Eur Respir J 38:1368-1373, 2011.
PubMed
3) 非侵襲的換気療法研究会:慢性呼吸不全に対する非侵襲的換気療法ガイドライン. Therapeutic Research 25:7-9, 2004.
 
4) Sin D D, et al:Risk factors for central and obstructive sleep apnea in 450 men and women with collgestive heart failure. Am Respir Crit Care Med 160:1101-1106,1999.
PubMed
5) Pena T, et al:Aspergillus lung disease in patients with sarcoidosis:a case series and review of literature. Lung 189:167-172, 2011.
PubMed
6) Akira M, et al:Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest 127:185-191, 2005.
PubMed
7) 立花暉夫, 他:大阪地区サルコイドーシス症例の合併症に関する検討. 日サ会誌 24:31-35, 2004.
 
8) Gupta D, et al:Interferon gamma assay (QuantiFERON-TB Gold in Tube) in patients of sarcoidosis from a population with high prevalence of tuberculosis infection. Sar Vasc Diffuse Lung Dis 28:95-101, 2011.
 
9) 森松嘉孝, 他:難知性肝病変を呈したサルコイドーシスへの長期ステロイド投与中, 重症ニューモシスティス・カリニ肺炎を発症した一例. 日サ会誌 22:69-73, 2002.
 
10) Yan L I U, et al:Recurrent pneumothoraxas a presenting manifestation of active sarcoidosis:a case report and literature review. Chin Med Rev 123:1615-1616, 2010.
 
11) Corte T J, et al:Pulmonary hypertension insarcoidosis:a review. Respirology 16:69-77, 2011.
PubMed
12) Kreider M, et al:Candidate selection, timing of listing, and choice of procedure for lung transplantation. Clin Chest Med 32:199-211, 2011.
PubMed
13) Shorr A F, et al:Sarcoidosis, race and short-term outcomes following lung transplantation. Chest Ur 125:990-996, 2004.
 
14) Shlobin O A, et al:Management of endstage sarcoidosis:pulmonary hypertension and lung transplantation. Eur Respir 2012(Express).
 
P.193 掲載の参考文献
1) Nagai S, et al:Outcome of sarcoidosis. Clin Chest Med 29(3):565-574, 2008.
PubMed
2) Morimoto T, et al:Epidemiology of sarcoidosis in Japan. Eur Respir J 31(2):372-379, 2008.
PubMed
3) Baughman R P, et al:Defining the clinical outcome status (COS) in sarcoidosis:results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis 28(1):56-64, 2011.
 
4) 長井苑子 間質性肺疾患:外来診療の実際. 医学書院, 東京, 2007.
 
5) Baughman R P, et al:Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 164(10 Pt 1):1885-1889, 2001.
 
6) Judson M A, et al:Two year prognosis of sarcoidosis:the ACCESS experience, Sarcoidosis Vasc Diffuse Lung Dis 20(3):204-211, 2003.
PubMed
7) Lynch J p 3rd, et al:Pulmonary sarcoidosis. Clin Chest Med 18(4):755-785, 1997.
PubMed
8) Akira M, et al:Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest 127(1):185-191, 2005.
PubMed
9) Handa T, et al:Clinical and radiographic indices associated with airflow limitation in patients with sarcoidosis. Chest 130(6):1851-1856, 2006.
PubMed
10) Handa T, et al:Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 1297(5):1246-1252, 2006.
 
11) The registry of the international society for heart and lung transplantation:27 annual report 2010. J Heart and Lung Transplantation 29:1083-1141, 2010.
 
12) Shlobin O A, et al:Management of endstage sarcoidosis:pulmonary hypertension and lung transplantation. Eur Respir J (Epub ahead of print)
 
13) Nardi A, et al:Stage IV sarcoidosis:comparison of survival with the general population and causes of death. Eur Respir 38(6):1368-1373, 2011.
PubMed
14) Yazaki Y, et al:Prognostic determinants long-term survival in Japanese patient with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88(9):1006-10 2001.
PubMed
15) Hamzeh N Y, et al:Management of card sarcoidosis in the United States:adelp study. Chest 141(1):154-162, 2012.
 
16) Gottlieb J E, et al:Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 111(3):623-631,1997.
PubMed
17) Baughman R P, et al:Infliximab Therapy Patients with Chronic Sarcoidosis and Pulmonary Involvement. Am J Respir Crit care Med 174:795-802, 2006.
PubMed

第5章 肺外サルコイドーシス

P.202 掲載の参考文献
1) 森本泰介,他:2004年サルコイドーシス疫学学調査.日サ会誌 27:103-108, 2007.
 
2) Goto H, et al:Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol 51:41-44, 2007.
PubMed
3) 渋谷悦子,他:横浜市立大学附属病院における近年のぶどう膜炎の疫学的検討(2009年～2011年). 臨眼 2012(印刷中)
 
4) 日本眼炎症学会・日本サルコイドーシス/肉芽腫性疾患学会:サルコイドーシスの診断基準と診断の手引き-2006. 日眼会誌 111:117-121, 2007.
 
5) 渋谷悦子,他:新診断基準を用いた眼病変からのサルコイドーシスの診断. 臨眼 63:1917-1922, 2009.
 
6) 石原麻美,他:サルコイドーシス臨床診断基準の見直し. 眼紀 57:114-118, 2006.
 
7) Asukata U, et al:Guidelines for the Diagnosis of Ocular sarcoidosis. Ocular Immunol Inflam 16:77-81, 2008.
 
8) 日本サルコイドーシス/肉芽腫性疾患学会:サルコイドーシス治療に関する見解-2003. 日サ会誌 23:105-114, 2003.
 
9) Kiltz U, et al:Use of methotrexate in patients with sarcoidosis. Exp Rheumatol 28 (suppl 61):S183-S185,2010.
 
10) Kawagoe T, et al:Sarcoidosis. Cur Opin Ophthalmol 22:502-507, 2011.
 
11) 藤井さゆり,他:ぶどう膜炎診療の新たな動向. 外科的治療. あたらしい眼科 28:489-494,2011.
 
12) 加賀玲子,他:高齢者のサルコイドーシスに伴うぶどう膜炎の検討. 眼紀 56:542-546, 2005.
 
P.209 掲載の参考文献
1) サルコイドーシスの診断基準と診断の手引き-2006. 日サルコイドーシス肉芽腫会誌 27(1):89-102, 2007.
 
2) 福代良一:サルコイドーシス. 現代皮膚科学会大系第18巻7(清寺真, 他 編) p27-359. 中山書店, 東京, 1988.
 
3) 岡本祐之:サルコイドーシス. 最新皮膚科学会大系第9巻 p258-270. 中山書店, 東京, 2002.
 
4) 岡本祐之:サルコイドーシス. 診断における癩痕浸潤の重要性. Visual Dermatol 2(4):327-33, 2003.
 
5) Okamoto H, et al:Cutaneous sarcoidosis with cardiac involvement. Eur J Dermatol 9(6):466-469, 1999.
PubMed
6) Yamada S, et al:A case of extensive subcutaneous sarcoidosis. J Dermatol 13(3):217-221, 1986.
 
7) Fujii K, et al:Recurrent follicular and lichenoid papules. Eur J Dermatol 10(4):303-305, 2000.
PubMed
8) Okamoto H, et al:Erythema nodosum-like eruption in sarcoidosis. Clin Experiment Dermatol 19(6):507-510, 1994.
 
P.218 掲載の参考文献
1) 金澤伸雄:若年発症サルコイドーシス. 最新皮膚科学体系2006-2007, pp205-209. 中山書店, 東京,2006.
 
2) Kambe N, et al:The cytosolic pattern-recognition receptor Nod2 and inflammatory granulomatous disorders. J Dermatol Sci 39:71-80, 2005.
PubMed
3) Blau E B:Familial granulomatous arthritis, iritis, and rash. J Pediatr 107:689-693, 1985.
 
4) Miller J J 3rd:Early-onset "sarcoidosis" and "familial granulomatous arthritis (arteritis)":the same disease. J pediatr 109:387-388, 1986.
 
5) Hugot Jp, et al:Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411:599-603, 2001.
PubMed
6) Ogura Y, et al:A frameshift mutation in Nod2 associated with susceptibility to Crohn's disease. Nature 411:603-606, 2001.
PubMed
7) Miceli-Richard C, et al:CARD15 mutations in Blau syndrome. Nat Genet 29:19-20, 2001.
 
8) Kanazawa N, et al:Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-κB activation:common genetic etiology with Blau syndrome. Blood 105:1195-1197, 2005.
 
9) Rose C D, et al:Pediatric granulomatous arthritis:an international registry. Arthritis Rheum 54:3337-3344, 2006.
PubMed
10) Okafuji I, et al:Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum 60:242-250, 2009.
PubMed
11) Sakai H, et al:A case of early-onset sarcoidosis with a six-base deletion in the NOD2 gene. Rheumatology (Oxfbrd)49:194-196, 2010.
 
12) 神戸直智, 他:若年発症サルコイドーシス/Blau症候群. 日臨免誌 34:378-381, 2011.
 
13) Sato H, et al:CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. Eur Respir J 35:324-330, 2010.
PubMed
14) Zhang F R, et al:Genomewide association study of leprosy. N Eng J Med 361:2609-2618, 2009.
 
15) McDermott M F, et al:Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFRI, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133-144, 1999.
 
16) Kanazawa N, et al:Autoinflammatory syndromes with a dermatological perspective.J Dermatol 34:601-618, 2007.
PubMed
17) Masumoto J, et al:Interleukin-1 beta suppression in Blau syndrome:comment on the article by Martin et al. Arthritis Rheum 60:2544-2545, 2009.
PubMed
18) Yasui K, et al:Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome. Arthritis Rheum 62:250-257, 2010.
PubMed
19) Rose C D, et al:Blau syndrome revisited. Curr Opin Rheumatol 23:411-418, 2011.
PubMed
20) Kanazawa N:Sarcoidosis and autoinfiammation. Inflam Regen 31:66-71, 2011.
 
P.226 掲載の参考文献
1) Iwai K, et al:Racial difference in cardiac sarcoidosis incidence observed at autopsy, Sarcoidosis 11:26-31, 1994.
PubMed
2) 矢崎善一, 他:心臓サルコイドーシスの臨床像. 心臓 43:1173-1175, 2011.
Medical*Online
3) 矢崎善一, 他:心臓サルコイドーシス-臨床病理学的多様性. 呼と循 46:37-46, 1998.
 
4) 平賀洋明, 他:心臓サルコイドーシス診断の手引き-1992-作製の経過について. 厚生省特定疾患びまん性肺疾患調査研究班平成4年度研究報告書, p23, 1993,
 
5) 森本紳一郎, 他:心臓サルコイドーシスの診断の手引きの改訂. 呼と循 54:955-961, 2006.
 
6) Valantine H, et al:Sarcoidosis:a pattern of clinical and morphological presentation. Br Heart J 57:256-263, 1987.
PubMed
7) Yazaki Y, et al:Cardiac sarcoidosis mimicking hypertrophic cardiomyopathy:clinicalutility of radionuclide imaging for differential diagnosis. Jpn Circl J 62:465-468, 1998
 
8) Smedema J P, et al:Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis ofcardiac sarcoidosis. J Am Coll Cardiol 45:1683-1690, 2006.
 
9) Okumura W, et al:Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 45:19891998, 2004.
 
10) Yamagishi H, et al:Identification of cardiac sarcoidosis with (13)N-NH7(3)/(18) F-FDGPET. J Nucl Med 44:1030-1036, 2003.
 
11) Ishimaru S, et al:Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 26:1538-1543, 2005.
PubMed
12) 日本サルコイドーシス/肉芽腫性疾患学会, 日本呼吸器学会, 日本心臓病学会, 日本眼科学会, 厚生省科学研究-特定疾患対策事業-びまん性肺疾患研究班編集:サルコイドーシス治療に関する見解-2003. 日本サルコイドーシス/肉芽腫性疾患学会ホームページ7(http://jssog.com/)
 
13) Caporali R, et al:Prednisone plus methotrexate fbr polymyalgia rheumatic-a randomized, double blind, placebo-controlled trial. Ann Intern Med 141:493-500, 2004.
 
14) Aizer A, et al:Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol 96:276-282, 2005.
PubMed
15) ACC/AHA/HRS 2008 guideline for device based therapy of cardiac rhythm abnormalities. Circulation 117:e350-408, 2008.
 
16) Yager J E, et al:Recurrence of cardiac sarcoidosis in a heart transplant recipient. J Heart Lung Transplant 24:1988-1990, 2005.
 
17) 矢崎善一, 他:心サルコイドーシスの治療. 呼と循 54:963-969, 2006.
 
18) 江石義信:サルコイドーシスの病因. 呼と循 54:915-923, 2006.
 
19) Yazaki Y, et al:Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88:1006-1010, 2001.
PubMed
20) Yazaki Y, et al:Infiuence of Recent Advances in the Management of Heart Failure and Ventricular Arrhythmias on Survival in Patients with Cardiac Sarcoidosis. Circulation 118 (Abstract), 2008.
 
21) Ardehali H, et al:A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 150:459-463, 2005.
PubMed
P.240 掲載の参考文献
1) Stern B J, et al:Sarcoidosis and Its Neurological Manifestations. Arch Neurol 42:909-917, 1985.
PubMed
2) Zajicek J P, et al:Central nervous system sarcoidosis-diagnosis and management. QJ Med 92:103-117, 1999.
 
3) 飯塚高浩, 他:神経サルコイドーシス. 日臨 607(9):1785-1793, 2002.
 
4) 折津愈:神経サルコイドーシスの診断と治療. 日胸 627(7):608-615, 2003.
 
5) 森下宗彦:サルコイドーシスの神経病変. 呼吸 227(4):358-363, 2003.
 
6) Hoitsma E, et al:Neurosarcoidosis:a clinical dilemma. Lancet Neuro 13:397-407, 2004.
 
7) Scott T F, et al:Neurosarcoidosis Mimicry of Multiple Sclerosis Clinical, Laboratory, and Imaging Characteristics. The Neurologist 16(6):386-389, 2010.
PubMed
8) Hamatani S, et al:Neurosarcoidosis Without Systemic Sarcoidois-Case Report Neurol Med Chir 41:48-51, 2001.
 
9) 作田学, 他:サルコイドーシスの神経・筋病変に関する診断基準. 脳神経 587(6):471-476, 2006.
 
10) 津田富康, 他, サルコイドーシス診断基準改定委員会:サルコイドーシスの診断基準と診断の手引き-2006. 日サ会誌 277(1):89-102, 2007.
 
11) 泉孝英:サルコイドーシスの臨床像. サルコイドーシスとその他の肉芽腫性疾患.7(安藤正幸, 他 監修) p26-34. 克誠堂出版, 東京, 2006.
 
12) 武村民子:サルコイドーシスにおける髄膜脳炎と脳内肉芽腫. 神経内科 45:197-204, 1996.
 
13) 森本耕三, 他:尿崩症と視床下部-下垂体-性腺系の機能障害を呈したサルコイドーシスの1例. 日サ会誌 27:43-47, 2007.
 
14) 松田希, 他:サルコイド脊髄症と変形性脊椎症. 日サ会誌 29(1):15-19, 2009.
 
15) 池田洋一郎, 他:小径線維ニューロパチー(small fiber neuropathy) を認めたサルコイドーシスの2症例. 日サ会誌 24:65-69, 2004.
 
16) Ginat D T, et al:Magnetic Resonance Imaging of Neurosarcoidosis. J Clin Imag Sci 1:1-8, 2011.
 
17) Moravan M, et al:Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 72:337-340, 2009.
PubMed
18) Pereira J, et al:Medically refractory neurosarcoidosis treated with infliximab. Inten Med J 41(4):354-357, 2011.
 
19) 森本泰介, 他:2004年サルコイドーシス疫学調査. 日サ会誌 277(1):103-108, 2007.
 
20) 熊本俊秀:診断基準の評価と今後検討すべき課題:神経・筋サルコイドーシスの視点から. 日サ会誌 297(1):81-82, 2009.
 
P.248 掲載の参考文献
1) Silverstein A, et al:Muscle involvement in sarcoidosis:Asymptomatic, myositis, and myopathy. Arch Neurol 24(3):235-2341, 1969.
 
2) 日本サルコイドーシス/肉芽腫性疾患学会, 他:サルコイドーシスの診断基準と診断の手引き-2006, 日呼吸会誌 46(9):768-780, 2008.
 
3) Jamal M M, et al:Sarcoidosis presenting as acute myositis:Report and review of the literature. J Rheumatol 15(12):1868-1871, 1988.
PubMed
4) 西武孝浩, 他:四肢筋に広範に伸展した腫瘤型筋サルコイドーシス. 日サ会誌 26(1):51-56, 2006.
 
5) Fayad F, et al:Systemic sarcoidosis:the "leopard-man"sign. Joint Bone Spine 73(1):109-112, 2006.
PubMed
6) 熊本俊秀:サルコイド筋炎. Clin Neurosci 30(3):332-334, 2012.
 
7) Otake S:Sarcoidosis involving skeletal muscle:imaging findings and relative value of imaging Procedures. AJR Am J Roentgenol 162(2):369-375, 1994.
PubMed
8) 熊本俊秀:診断基準の評価と今後検討すべき課題:神経・筋サルコイドーシスの視点から. 日サ会誌 29(1):81-82, 2009.
 
9) Kumamoto T, et al:Cellular distribution of proteolytic enzymes in the skeletal muscle of sarcoid myopathy. Acta Neuropathol 104(1):38-44, 2002.
PubMed
10) 熊本俊秀:サルコイドーシスの臓器病変:神経・筋肉. サルコイドーシスとその他の肉芽腫性疾患4版7(安藤正幸, 他 監), p87(F87. 克誠堂, 東京, 2009.
 
11) 竹丸 誠, 他:Lobulated fubersを伴った慢性ミオパチ-型筋サルコイドーシスと考えられた1例. 日サ会誌 31(1):49-55, 2011.
 
12) Androdias G, et al:Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 76(13):1168-1172, 2011.
 
13) Uddenfeldt P, et al:Musculo-skeletal symptoms in early sarcoidosis. Twentyfour newly diagnosed patients and a twoyear follow-up. Acta Med Scand 214(4):279-284, 1983.
 
14) Zisman D A, et al:Sarcoidosis involving the musculoskeletal system. Semin Respir Crit Care Med 23(6):555-570, 2002.
PubMed
15) Oliver S J:Nonpulmonary manifestations of sarcoidosis. Curr Rheumatol Rep 4(2):170-178, 2002.
PubMed
16) Awada H, et al:Musculoskeletal and other extrapulmonary disorders in sarcoidosis. Best Pract Res Clin Rheumatol 17(6):971-987, 2003.
PubMed
17) Resnick D, et al:Diagnosis of Bone and Joint disorders. WB Saunders Company, Philadelphia, 2002.
 
18) 伊東武雄:病的骨折をきたした骨サルコイドーシスの1例. 日サ会誌 257(1):45-51, 2005.
 
19) DiCarlo E F, et al:Inflammatory diseases of the bones and joints. Semin Diagn Pathol 287(1):53-64, 2011.
 

書評

最近チェックした商品履歴

Loading...